Nexien BioPharma Reports Decreased Net Losses and Ongoing Financial Challenges

Nexien BioPharma, Inc. reported its financial results for the three and nine months ended March 31, 2025, revealing a net loss of $30,092 for the quarter, a decrease of 43% from the $53,163 loss recorded in the same period of the previous year. For the nine-month period, the company reported a net loss of $101,568, down from $152,599 in the prior year. The reduction in losses is attributed to decreased general and administrative expenses, which fell to $15,997 for the nine months ended March 31, 2025, compared to $63,548 for the same period in 2024, primarily due to the absence of non-cash stock-based compensation costs.

The company continues to face significant financial challenges, with total current liabilities increasing to $458,801 as of March 31, 2025, compared to $365,432 at June 30, 2024. This increase is largely due to rising accounts payable and accrued expenses, which reached $83,426, up from $53,178 in the previous fiscal period. Nexien's working capital deficit also widened to $450,516 from $361,249, reflecting ongoing cash utilization for operational expenses. The company ended the reporting period with cash and cash equivalents of $8,285, a notable increase from $4,183 at the end of the previous fiscal year.

Nexien has not generated any revenue from operations, as it has ceased research and development activities due to insufficient working capital. The company is actively seeking additional funding to support its operations and is exploring potential merger or business combination opportunities. During the nine months ended March 31, 2025, Nexien raised $2,076,158 in equity capital and $246,750 from debt issuances, but it estimates needing at least $40,000 to maintain its public company status for the remainder of the fiscal year.

The company’s operational metrics indicate a stable employee headcount, with 70,772,196 shares of common stock outstanding as of May 13, 2025. However, Nexien's financial outlook remains uncertain, as it has not established a reliable source of revenue and continues to incur operating losses. The management has expressed substantial doubt about the company's ability to continue as a going concern without significant capital infusion or successful business restructuring.

Looking ahead, Nexien BioPharma emphasizes the need for substantial additional funding to advance its drug development programs and cover operational costs. The company has not yet secured commitments for the required capital, and its future operations will depend heavily on its ability to raise funds or enter into strategic partnerships. The management's forward-looking statements highlight the challenges of navigating the lengthy and capital-intensive process of pharmaceutical development, particularly in the context of regulatory approvals and market adoption of its future drug candidates.